Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $937.9 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 94.14% year-over-year to $937.9 million; the TTM value through Dec 2025 reached $2.3 billion, up 42.43%, while the annual FY2025 figure was $937.9 million, 94.14% up from the prior year.
  • Liabilities and Shareholders Equity reached $937.9 million in Q4 2025 per PRAX's latest filing, up from $396.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $937.9 million in Q4 2025 and bottomed at $87.9 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 4 years is $309.7 million, with a median of $245.0 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 58.92% in 2023, then surged 449.31% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $115.1 million in 2022, then decreased by 23.61% to $87.9 million in 2023, then soared by 449.31% to $483.1 million in 2024, then skyrocketed by 94.14% to $937.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $937.9 million in Q4 2025, $396.4 million in Q3 2025, and $452.8 million in Q2 2025.